Q1-FY25 · Q4 FY24
India growth to outperform IPM by 2-3%
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
TORNTPHARM / Q2-FY26 / promises
Measure what management said.
Torrent Pharmaceuticals · A quarter-by-quarter view of forward statements and whether delivery is visible yet.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Management delivery ledger
Promises over time.
Q1-FY25 · Q4 FY24
Brazil growth target of 14-15% in FY25
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q1-FY25 · Q4 FY24
Germany growth at high single digit
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q1-FY25 · Q4 FY24
50-100bps EBITDA margin expansion in FY25
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q1-FY26 · Q4 FY25
India MR Expansion to 6,800-6,900
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q1-FY26 · Q4 FY25
Brazil Double-Digit Constant Currency Growth
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q1-FY26 · Q4 FY25
R&D Spend Increasing to ~5.4%
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q1-FY26 · Q4 FY25
U.S. Launches: 7-8 Products in Next 12 Months
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q2-FY24 · Q1 FY24
Margin maintenance at 30%+
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q2-FY24 · Q1 FY24
75-100bps annual margin improvement
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q2-FY24 · Q1 FY24
Brazil H2 pickup with ~6 launches
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q2-FY24 · Q1 FY24
Germany Q4 recovery
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q2-FY25 · Q1 FY25
India Business Growth: 13-15% for FY25
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q2-FY25 · Q1 FY25
Brazil Growth: 12-13% underlying rate
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q2-FY25 · Q1 FY25
U.S. FDA Resolution: October 2024
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q2-FY25 · Q1 FY25
Tax Rate: 30% for FY25, 26-27% from FY27
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q2-FY26 · Q1 FY26
Minimum 32.9% EBITDA margin to sustain for FY2026
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q2-FY26 · Q1 FY26
Target 6,900-7,000 MRs by FY26 year-end
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q2-FY26 · Q1 FY26
~10 product launches planned in U.S. for FY2026
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q2-FY26 · Q1 FY26
Brazil: 8-10 product launches per year
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q3-FY24 · Q2 FY24
U.S. revenue run rate of $30-35 million per quarter
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
met
heuristic_v1
Q3-FY24 · Q2 FY24
Gross margin sustainably at 75%
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
met
heuristic_v1
Q3-FY24 · Q2 FY24
India market growth at 7-8%, Torrent base at 12%
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
met
heuristic_v1
Q3-FY24 · Q2 FY24
Net debt/EBITDA below 1x by March 2024
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
met
heuristic_v1
Q3-FY25 · Q2 FY25
Brazil: Double-digit top-line growth, H2 traditionally stronger
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q3-FY26 · Q2 FY26
India field force expansion to 7,000 reps by FY26 year-end
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q3-FY26 · Q2 FY26
Germany supply disruption normalization by Q4 FY26
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q3-FY26 · Q2 FY26
Annual CapEx of INR 250-300 crore over next 3 years
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q3-FY26 · Q2 FY26
New therapy division entry in India by Q4 FY26
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q4-FY24 · Q3 FY24
31.8% EBITDA margin as new sustainable base
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q4-FY24 · Q3 FY24
7-8 U.S. product launches in Q1 FY25
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q4-FY24 · Q3 FY24
R&D spend to be 5-5.5% in FY25, 5.5-6% in FY26
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q4-FY24 · Q3 FY24
Germany incremental revenue from Q2 FY25
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q4-FY25 · Q3 FY25
Margin Improvement: 50-100 bps annually
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1